These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23410153)

  • 21. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
    Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
    Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
    Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
    Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
    Rosenberg L; Yoon CH; Sharma G; Bertagnolli MM; Cho NL
    Carcinogenesis; 2018 May; 39(5):681-688. PubMed ID: 29538717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM kinase (and Akt) biology and signaling in tumors.
    Warfel NA; Kraft AS
    Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
    Wang P; Zhang L; Hao Q; Zhao G
    Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulation of the Akt pathway in human cancer.
    Tokunaga E; Oki E; Egashira A; Sadanaga N; Morita M; Kakeji Y; Maehara Y
    Curr Cancer Drug Targets; 2008 Feb; 8(1):27-36. PubMed ID: 18288941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
    Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
    Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maximising the potential of AKT inhibitors as anti-cancer treatments.
    Brown JS; Banerji U
    Pharmacol Ther; 2017 Apr; 172():101-115. PubMed ID: 27919797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Akt in cancer for precision therapy.
    Hua H; Zhang H; Chen J; Wang J; Liu J; Jiang Y
    J Hematol Oncol; 2021 Aug; 14(1):128. PubMed ID: 34419139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
    Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
    Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.